221 related articles for article (PubMed ID: 36053960)
21. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
[TBL] [Abstract][Full Text] [Related]
22. [Alendronate increases bone mineral density in patients with symptomatic primary hyperparathyroidism].
Misiorowski W
Endokrynol Pol; 2005; 56(6):871-5. PubMed ID: 16821204
[TBL] [Abstract][Full Text] [Related]
23. Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic.
Alfadhli EM
Clin Ther; 2021 Apr; 43(4):711-719. PubMed ID: 33752899
[TBL] [Abstract][Full Text] [Related]
24. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
25. The evolution of primary hyperparathyroidism publications and global productivity from past to present: A bibliometric analysis during 1980 to 2022.
Göbüt H; Bostanci H
Medicine (Baltimore); 2023 Sep; 102(35):e34622. PubMed ID: 37657020
[TBL] [Abstract][Full Text] [Related]
26. Interventions for preventing bone disease in kidney transplant recipients.
Palmer SC; Chung EY; McGregor DO; Bachmann F; Strippoli GF
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD005015. PubMed ID: 31637698
[TBL] [Abstract][Full Text] [Related]
27. Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis.
Sekercioglu N; Busse JW; Mustafa RA; Guyatt GH; Thabane L
Syst Rev; 2016 Jan; 5():2. PubMed ID: 26729302
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
Khan AA; Rubin MR; Schwarz P; Vokes T; Shoback DM; Gagnon C; Palermo A; Marcocci C; Clarke BL; Abbott LG; Hofbauer LC; Kohlmeier L; Pihl S; An X; Eng WF; Smith AR; Ukena J; Sibley CT; Shu AD; Rejnmark L
J Bone Miner Res; 2023 Jan; 38(1):14-25. PubMed ID: 36271471
[TBL] [Abstract][Full Text] [Related]
29. Surgical Aspects of Primary Hyperparathyroidism.
Perrier N; Lang BH; Farias LCB; Poch LL; Sywak M; Almquist M; Vriens MR; Yeh MW; Shariq O; Duh QY; Yeh R; Vu T; LiVolsi V; Sitges-Serra A
J Bone Miner Res; 2022 Nov; 37(11):2373-2390. PubMed ID: 36054175
[TBL] [Abstract][Full Text] [Related]
30. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
Duntas LH; Stathatos N
Endocrine; 2011 Jun; 39(3):199-204. PubMed ID: 21442382
[TBL] [Abstract][Full Text] [Related]
31. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.
Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C
J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564
[TBL] [Abstract][Full Text] [Related]
32. Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series.
Zamoner SMS; Takase HM; Riyuzo MC; Caramori JCT; de Andrade LGM
Int Urol Nephrol; 2024 May; 56(5):1669-1676. PubMed ID: 37964112
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.
Puliani G; Hasenmajer V; Simonelli I; Sada V; Pofi R; Minnetti M; Cozzolino A; Napoli N; Pasqualetti P; Gianfrilli D; Isidori AM
J Bone Miner Res; 2022 Jul; 37(7):1233-1250. PubMed ID: 35485213
[TBL] [Abstract][Full Text] [Related]
34. Update on the use of cinacalcet in the management of primary hyperparathyroidism.
Marcocci C; Cetani F
J Endocrinol Invest; 2012 Jan; 35(1):90-5. PubMed ID: 22104762
[TBL] [Abstract][Full Text] [Related]
35. Asymptomatic primary hyperparathyroidism: surgical and medical management.
Francucci CM; Ceccoli L; Caudarella R; Rilli S; Vescini F; Boscaro M
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):50-4. PubMed ID: 21985981
[TBL] [Abstract][Full Text] [Related]
36. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism.
Bollerslev J; Marcocci C; Sosa M; Nordenström J; Bouillon R; Mosekilde L
Eur J Endocrinol; 2011 Dec; 165(6):851-64. PubMed ID: 21964961
[TBL] [Abstract][Full Text] [Related]
37. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
Peacock M; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2009 Dec; 94(12):4860-7. PubMed ID: 19837909
[TBL] [Abstract][Full Text] [Related]
38. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop.
Bilezikian JP; Khan AA; Silverberg SJ; Fuleihan GE; Marcocci C; Minisola S; Perrier N; Sitges-Serra A; Thakker RV; Guyatt G; Mannstadt M; Potts JT; Clarke BL; Brandi ML;
J Bone Miner Res; 2022 Nov; 37(11):2293-2314. PubMed ID: 36245251
[TBL] [Abstract][Full Text] [Related]
39. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism.
Minisola S; Arnold A; Belaya Z; Brandi ML; Clarke BL; Hannan FM; Hofbauer LC; Insogna KL; Lacroix A; Liberman U; Palermo A; Pepe J; Rizzoli R; Wermers R; Thakker RV
J Bone Miner Res; 2022 Nov; 37(11):2315-2329. PubMed ID: 36245271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
